SuperworthAdma Biologics profit margin ADMA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.
- Net margin, 12 months
- 33.0%
- Operating margin, 12 months
- 43.8%
- Net margin on a year earlier
- −11.1 pts
- Peer median
- 20.9%
Over the twelve months to Jun 30, 2026, Adma Biologics kept 33.0% of its revenue as net profit, with an operating margin of 43.8% and a gross margin of 64.7%.
The median for 9 biotech stocks of a similar size is 20.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 28.8% | 37.5% | 57.4% |
| FY2024 | 46.4% | 32.6% | 51.5% |
| FY2023 | −10.9% | 8.4% | 34.4% |
| FY2022 | −42.8% | −25.5% | 22.9% |
| FY2021 | −88.5% | −72.1% | 1.4% |
| FY2020 | n/a | n/a | −45.2% |
| FY2019 | n/a | n/a | −34.6% |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | −28.1% |
| FY2016 | n/a | n/a | 40.3% |
| FY2015 | n/a | n/a | 39.9% |
| FY2014 | n/a | n/a | 36.7% |
| FY2013 | n/a | n/a | 34.0% |
| FY2012 | n/a | n/a | 40.2% |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 33.0% | −11.1 pts | 43.8% | |
| Q1 FY26 | 32.4% | −12.6 pts | 42.1% | |
| Q4 FY25 | 28.8% | −17.6 pts | 37.5% | |
| Q3 FY25 | 42.9% | +25.1 pts | 34.2% | |
| Q2 FY25 | 44.1% | +33.5 pts | 32.8% | |
| Q1 FY25 | 45.0% | +46.3 pts | 33.1% | |
| Q4 FY24 | 46.4% | +57.3 pts | 32.6% | |
| Q3 FY24 | 17.8% | +27.5 pts | 30.0% | |
| Q2 FY24 | 10.5% | +29.9 pts | 25.4% | |
| Q1 FY24 | −1.3% | +24.9 pts | 15.6% | |
| Q4 FY23 | −10.9% | +31.8 pts | 8.4% | |
| Q3 FY23 | −9.7% | +44.2 pts | 0.6% |
Against its peers
Companies in Biotechnology nearest Adma Biologics' size, closest first, today.
| Company | Profit margin |
|---|---|
| ADMAAdma Biologics | 33.0% |
| VCELVericel | 7.9% |
| MGTXMeiraGTx | 19.9% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| Peer median | 20.9% |
Where Adma Biologics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Adma Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.